THE ECONOMIC BURDEN OF COMMON DERMATOLOGICAL DISEASES

Öz

Skin diseases are among the most common diseases worldwide. In addition to the costs incurred by individuals, their costs to health systems and the country's economy can not be ignored. Fort he reason that, there are no cost analysis researchs in our country, USA based sources were used for this review. Cost analysis studies on psoriasis, atopic dermatitis, chronic wounds and malignant melanoma, which are the most common or most costly dermatological diseases, have been mentioned in this review

Anahtar Kelimeler

• Economic,burden,dermatological,diseases

SIK GÖRÜLEN DERMATOLOJİK HASTALIKLARIN EKONOMİK YÜKÜ

Öz

Deri hastalıkları tüm Dünya’da en yaygın görülen hastalıklardandır. Bireylere getirdiği masrafların yanı sıra, sağlık sistemlerine ve ülke ekonomisine olan maliyetleri göz ardı edilemez düzeydedir. Ülkemizde yapılmış herhangi bir maliyet hesabı olmamakla birlikte, daha çok Amerika Birleşik Devletleri merkezli kaynaklardan yararlanılan bu derlemede, en sık görülen veya maliyeti en fazla olan, başta psoriasis hastalığı olmak üzere, atopik dermatit, kronik yaralar ve malign melanom konularında yapılmış maliyet analizi çalışmalarından bahsedilmiştir

Anahtar Kelimeler

• Deri hastalıkları,ekonomik,yük

Kaynakça

1. 1. Thorpe KE, Florence CS, Joski P. Which medical conditions account for the rise in health spending? Health Aff (Millwood) 2004;22:W4-437-45.
2. 2. Johnson ML. Defining the burden of skin disease in the United Statesea historical perspective. J Investig Dermatol Symp Proc 2004;9:108-10.
3. 3. Dehkharghani S. The economic burden of skin diseases in the United States. J Am Acad Dermatol 2003;48:592-9.
4. 4. Bickers DR, Lim HW, Margolis D, Weinstock MA, Goodman C, Faulkner E, Gould C, Gemmen E, Dall T; American Academy of Dermatology Association; Society for Investigative Dermatology. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol. 2006 Sep;55(3):490-500.
5. 5. Research expenditures provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases. National Institutes of Health 2005.
6. 6. Self-care in the new millennium. Roper Starch Worldwide. 2001. Available at: http://www.chpa-info.org/pdfs/CHPA%20Final%20 Report%20revised%20(03-20)_.pdf. Accessed July 2001.
7. 7. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J AmAcad Dermatol. 2014;70(3):512-16.
8. 8. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433-43.

9. 9. Neimann AL, Shin DB,Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J AmAcad Dermatol. 2006;55(5):829-35.
10. 10. Han C, Lofland JH, Zhao N, Schenkel B. Increased prevalence of psychiatric disorders and health care–associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2011;10(8):843-50.
11. 11. Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health Qual Life Outcomes 2006; 4: 35.
12. 12. Zachariae H. Prevalence of joint disease in patients with psoriasis: implications for therapy. Am J Clin Dermatol 2003; 4: 441–7.
13. 13. Gelfand JM, Neimann AL, Shin DB et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735–41.
14. 14. Cohen AD, Sherf M, Vidavsky L et al. Association between psoriasis and the metabolic syndrome. A cross-sectional study. Dermatology 2008; 216: 152–5.
15. 15. Levy AR, Davie AM, Brazier NC, Jivraj F, Albrecht LE, Gratton D, Lynde CW. Economic burden of moderate to severe plaque psoriasis in Canada. Int J Dermatol. 2012 Dec;51(12):1432-40.
16. 16. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet 2007; 370: 263–71.
17. 17. Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002;46:850–60.
18. 18. Brezinski EA, Dhillon JS, Armstrong AW. Economic Burden of Psoriasis in the United States: A Systematic Review. JAMA Dermatol. 2015 Jun;151(6):651-8. Review.
19. 19. Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis on health care costs and patient work loss. J AmAcad Dermatol. 2008;59(5):772-80.
20. 20. Yu AP, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin. 2009;25(10):2429-38.
21. 21. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. The direct healthcare insurer and out-of-pocket expenditures of psoriasis: evidence from a United States national survey. J Dermatolog Treat. 2012;23(4):240-54.
22. 22. Alora-Palli MB, Brouda I, Green B, Kimball AB. A cost-effectiveness comparison of liquor carbonis distillate solution and calcipotriol cream in the treatment of moderate chronic plaque psoriasis. Arch Dermatol. 2010;146(8):919-22.
23. 23. Staidle JP, Dabade TS, Feldman SR. A pharmacoeconomic analysis of severe psoriasis therapy: a review of treatment choices and cost efficiency. Expert Opin Pharmacother. 2011;12(13): 2041-54.
24. 24. Beyer V,Wolverton SE. Recent trends in systemic psoriasis treatment costs. Arch Dermatol. 2010;146(1):46-54.
25. 25. Yentzer BA, Yelverton CB, Simpson GL, et al. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis. Dermatol Online J. 2009;15(4):1.
26. 26. Villacorta R, Hay JW, Messali A. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics. 2013;31(9):823-39.
27. 27. Lin HC, Lucas PT, Feldman SR, Balkrishnan R. Medication use and associated health care outcomes and costs for patientswith psoriasis in the United States. J Dermatolog Treat. 2012;23(3):196-202.
28. 28. Bonafede MM, Gandra SR,Watson C, Princic N, Fox KM. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis. Adv Ther. 2012;29(3): 234-48.
29. 29. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9(2):136-9.
30. 30. Schmitt JM, Ford DE.Work limitations and productivity loss are associatedwith health-related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213(2):102-10.
31. 31. Kimball AB, Guérin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011 Feb;25(2):157-63.
32. 32. Crown WH, Bresnahan BW, Orsini LS et al. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin 2004; 20: 1929–36.
33. 33. Raimer SS. Managing pediatric atopic dermatitis. Clin Pediatr (Phila) 2000;39:1–14.
34. 34. Hauser C, Wuethrich B, Matter L, et al. Staphylococcus aureus skin colonization in atopic dermatitis patients. Dermatologica 1985;170:35–9.
35. 35. Lamb SR, Rademaker M. Pharmacoeconomics of drug therapy for atopic dermatitis. Expert Opin Pharmacother 2002;3:249–55.
36. 36. Kang S, Lucky AW, Pariser D, et al. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001;44:58– 64.
37. 37. Hanifin JM, Tofte SJ. Update on therapy of atopic dermatitis. J Allergy Clin Immunol 1999;104:123–5.
38. 38. Verboom P, Hakkaart-Van L, Sturkenboom M, et al. The cost of atopic dermatitis in the Netherlands: an international comparison. Br J Dermatol 2002;147:716–24.
39. 39. Lapidus CS, Schwarz DF, Honig PJ. Atopic dermatitis in children: who cares? Who pays? J Am Acad Dermatol 1993;28:699–703.
40. 40. Emerson RM, Williams HC, Allen BR. What is the cost of atopic dermatitis in preschool children? Br J Dermatol 2001;144:514–22.
41. 41. Ellis CN, Drake LA, Prendergast MM, et al. Cost of atopic dermatitis and eczema in the United States. J Am Acad Dermatol 2002;46:361–70.
42. 42. Fivenson D, Arnold RJ, Kaniecki DJ, et al. The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 2002;8:333–42.
43. 43. Geller AC, Miller DR, Swetter SM, Demierre M-F, Gilchrest BA. A call for the development and implementation of a targeted national melanoma screening program. Arch Dermatol. 2006;142(4):504-7.
44. 44. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999 to 2000. J Clin Oncol. 2004;22(17):3524-30.
45. 45. Seidler AM, Pennie ML, Veledar E, Culler SD, Chen SC. Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data. Arch Dermatol. 2010 Mar;146(3):249-56.
46. 46. Tsao H, Rogers GS, Sober AJ. An estimate of the annual direct cost of treating cutaneous melanoma. J Am Acad Dermatol. 1998;38(5, pt 1):669-80.